The Library
Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal 2 challenge with pneumonia virus of mice
Tools
Maunder, Helen E., Taylor, Geraldine, Leppard, Keith and Easton, A. J. (Andrew J.) (2015) Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal 2 challenge with pneumonia virus of mice. Vaccine, 33 (48). pp. 6641-6649. doi:10.1016/j.vaccine.2015.10.105 ISSN 0264-410X.
|
PDF
WRAP_Maunder_-jvac-d-15-01492_accepted.pdf - Accepted Version - Requires a PDF viewer. Download (2093Kb) | Preview |
|
|
PDF
WRAP_maunder_et_al_rad5_pvm_-_preprint.pdf - Submitted Version - Requires a PDF viewer. Download (1722Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.vaccine.2015.10.105
Abstract
Pneumonia virus of mice (PVM) infection of BALB/c mice induces bronchiolitis leading to a fatal pneumonia in a dose-dependent manner, closely paralleling the development of severe disease during human respiratory syncytial virus infection in man, and is thus a recognised model in which to study the pathogenesis of pneumoviruses. This model system was used to investigate delivery of the internal structural proteins of PVM as a potential vaccination strategy to protect against pneumovirus disease. Replication-deficient recombinant human adenovirus serotype 5 (rAd5) vectors were constructed that expressed the M or N gene of PVM pathogenic strain J3666. Intranasal delivery of these rAd5 vectors gave protection against a lethal challenge dose of PVM in three different mouse strains, and protection lasted for at least 20 weeks post-immunisation. Whilst the PVM-specific antibody response isuch animals was weak and inconsistent, rAd5N primed a strong PVM-specific CD8+ T cell response and, to a lesser extent, a CD4+ T cell response. These findings suggest that protection induced by rAd5N was mediated by T-cells rather than serum antibody.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QR Microbiology > QR355 Virology | ||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) | ||||||||||
Library of Congress Subject Headings (LCSH): | Viral pneumonia -- Vaccination, Vaccines, Intranasal medication, Adenoviruses | ||||||||||
Journal or Publication Title: | Vaccine | ||||||||||
Publisher: | Elsevier Ltd. | ||||||||||
ISSN: | 0264-410X | ||||||||||
Official Date: | 27 November 2015 | ||||||||||
Dates: |
|
||||||||||
Volume: | 33 | ||||||||||
Number: | 48 | ||||||||||
Page Range: | pp. 6641-6649 | ||||||||||
DOI: | 10.1016/j.vaccine.2015.10.105 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||||
Date of first compliant deposit: | 31 December 2015 | ||||||||||
Date of first compliant Open Access: | 1 November 2016 | ||||||||||
Funder: | Medical Research Council (Great Britain) (MRC) | ||||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year